Progressive deterioration of beta-cell function in nonobese type 2 diabetic subjects: Postprandial plasma C-peptide level is an indication of insulin dependency

Diabetes and Metabolism

Volumn 22, Issue 3, 1996, Pages 185-191

  Prando, R ^a,b   Odetti, P ^a   Melga, P ^a   Giusti, R ^a   Ciuchi, E ^a   Cheli, V ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

C peptide; Daily profile; Diabetes duration; Glucagon test; Secondary failure

Indexed keywords

C PEPTIDE; GLUCAGON; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CELL FUNCTION; DIAGNOSTIC TEST; DISEASE DURATION; FEMALE; HORMONE RELEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; C-PEPTIDE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; FOOD; GLUCAGON; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; LINEAR MODELS; MALE; MIDDLE AGED; OBESITY; STIMULATION, CHEMICAL; TREATMENT OUTCOME;

EID: 0030013749     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes, 1979, 28, 1039-1057.
2. Turner RC, Holman RR, Matthews DR, Peto J. Relative contributions of insulin deficiency and insulin resistance in maturity onset diabetes. Lancet, 1982, 1, 596-598.
3. Reaven GM. Insulin secretion and insulin action in non-insulin-dependent diabetes mellitus : which defect is primary ? Diabetes Care, 1984, 7 (Suppl. 1), 17-24.
4. De Fronzo RA. Pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus : A balanced overview. Diabetologia, 1992, 35, 389-397.
5. Taylor SI, Accili D, Imai Y. Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM ? Diabetes, 1994, 43, 735-739.
6. Unger RH, Grundy S. Hyperglycaemia as an inducer as well as a consequence of impaired islet function and insulin resistance : implications for the management of diabetes. Diabetologia, 1985, 28, 119-121.
7. Robertson RP, Olson LK, Zhang HJ. Differentiating glucose toxicity from glucose desensitization : a new message from the insulin gene. Diabetes, 1994, 94, 1085-1089.
8. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993, 329, 977-986.
9. Wales JK. Treatment of type 2 (non-insulin-dependent) diabetic patients with diet alone. Diabetologia, 1982, 23, 240-245.
10. Krall LP, Bradley RF. "Secondary failure" in the treatment of diabetes mellitus with tolbutamide and with phenformine. Diabetes, 1962, 11, 88-91.
11. Shen SW, Bressler R. Clinical pharmacology of oral antidiabetic agents. N Engl J Med, 1977, 296, 787-793.
12. DeLawter DE, Moss JM, Tyroler S. Secondary failure of response of tolbutamide treatment. JAMA, 1960, 171, 1786-1792.
13. Mehnert H. Clinical and experimental findings after five years' treatment of diabetes with sulfonylureas. Diabetes, 1962, 11, 80-84.
14. Groop L, Pelkonen R. Treatment failures : a common problem in the management of patients with type II diabetes. Acta Endocrinol, 1984, Suppl. 262, 131-135.
15. Camerini-Davalos RA, Marble A. Incidence and causes of secondary failure in treatment with tolbutamide : Experience with 2500 patients treated up to 5 years. JAMA, 1962, 181, 1-4.
16. Tang-Fuing S, Keen H, Jarrett RJ. Epidemiological study of prevalence of chlorpropamide alcohol flushing in insulin-dependent diabetics, non-insulin-dependent diabetics, and non-diabetics. Br Med J, 1983, 287, 1509-1512.
17. Groop LC, Pelkonen R, Koskimies S, Bottazzo GF, Doniach D. Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes. Diabetes Care, 1986, 9, 129-133.
18. Groop LC, Eriksson J, Schalin C, Ahola A. Does secondary oral failure represent slowly evolving type 1 diabetes ? In : Cameron D, Colagiuri S, Heding L, Kuhl C, Ma A, Mortimer R, eds. "Non-insulin dependent diabetes mellitus". Hong Kong : Excerpta Medica, 1989, 48-51.
19. Gutniak M, Karlander S, Efendic S. Glyburide decreases insulin requirement, increases beta-cell response to mixed meal, and does not affect insulin sensitivity : effects of short- and longterm combined treatment in secondary failure to sulfonylurea. Diabetes Care, 1987, 10, 545-554.
20. Seltzer HS, Harris VL. Exhaustion of insulinogenic reserve in maturity-onset diabetic patients during prolonged and continuous hyperglycemic stress. Diabetes, 1961, 13, 6-13.
21. Haupt E, Laube F, Ley H, Schoffling K. Secondary failures in modern therapy of diabetes mellitus with blood glucose-lowering sulfonamides. Med Klin, 1977, 72, 1529-1536.
22. Pontiroli AE, Calderara A, Maffi P, et al. Secondary failure to oral hypoglycemic agents in non-obese patients with non-insulin-dependent diabetes is related to reduced insulin release. Diabete Metab, 1989, 15, 79-84.
23. Lyons TI, Kennedy L, Atkinson AB, Buchanan KD, Hadden DR, Weaver JA. Predicting the need for insulin therapy in late onset (40-69 years) diabetes mellitus. Diabetic Med, 1984, 1, 105-107.
24. Snehalatha C, Ramachandran A, Mohan V, Timothy H, Viswanathan M. Beta-cell function in long-term NIDDM (type 2) patients and its relation to treatment. Horm Metabol Res. 1986, 18, 391-394.
25. Zimmerman BR, Service FJ. Management of non-insulin-dependent diabetes. Med Clin North Am, 1987, 72, 1355-1364.
26. Genuth S. Insulin use in NIDDM. Diabetes Care, 1990, 13, 1240-1264.
27. Kishikawa H, Hashimoto Y, Hashiguchi Y, et al. Insulin treatment regimes for type II (non-insulin-dependent) diabetes mellitus as judged by residual B-cell function. Diab Nutr Metab, 1991, 4, 305-312.
28. Alberti KGMM, Gries FA. Management of non-insulin-dependent diabetes mellitus in Europe : a consensus view. Diabetic Med, 1988, 5, 275-281.
29. Kaneto T, Oka H, Manemura M. Radioimmunoassay of human proinsulin and C-peptide using synthetic human connecting peptide. Endocrinol Japan, 1974, 21, 141-150.
30. Borissova AM, Koev DG, Minev MG, et al. Factors for development of secondary failure to sulfonylurea drugs in non-insulin-dependent diabetes mellitus. Acta Diabetol Lat, 1991, 28, 91-98.
31. Seltzer HS, Allen EW, Herron AC, Brennan MT. Insulin secretion in response to glycemic stimulus, relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest, 1967, 46, 323-335.
32. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D. Diminished beta-cell secretory capacity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest, 1984, 74, 1318-1328.
33. Pfeiffer MA, Halter JD, Porte D Jr. Insulin secretion in diabetes mellitus. Am J Med, 1985, 70, 579-588.
34. Olefsky JM, Kolterman OG. The insulin receptor in physiological and pathological conditions. In : Andreani D ed., "Current Views on Insulin Receptors". Serono Symposia. London - New York : Academic Press, 1981, 463-488.
35. Reaven GM, Chen Y-DI, Chen JG, Hollenbeck CB. Is the insulin resistance of patients with non-insulin-dependent diabetes mellitus secondary to insulin deficiency ? Horm Metabol Res, 1986, 18, 244-246.
36. Stenman S, Groop PH, Saloranta C, Totterman KJ, Fyhrquist F, Groop L. Effects of the combination of insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral hypoglycaemic agents. Diabetologia, 1988, 31, 206-213.
37. Del Prato S, Vigili de Kreutznberg S, Riccio A et al. Partial recovery of insulin secretion and action after combined insulin-sulfonylurea treatment in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral agents. Diabetologia, 1990, 33, 688-695.
38. Pontiroli AE, Dino G, Capra F, Pozza G. Combined therapy with glibenclamide and ultralente insulin in lean patients with NIDDM with secondary failure to sulphonylureas. Follow up at two years. Diabet Metab, 1990, 16, 323-327.
39. Liu G, Coulston A, Chen Y-DI, Reaven GM. Does day-long abslute hypoinsulinemia characterize the patient with non-insulin-dependent diabetes mellitus ? Metabolism, 1983, 32, 754-756.
40. Polonsky KS, Given BD, Hirsh LJ, et al. Abnormal patterns on insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med, 1988, 318, 1231-1239.
41. Cignarelli M, Cospite MR, Stefanelli G, Guastamacchia E, Mardelli G, Girgino R. Duration of residual beta-cell function in maturity onset diabetes. Acta Diabetol Lat, 1984, 21, 161-166.
42. Trischitta V, Italia S, Mazzarino S, Frittita L, Favetta A, Vigheri R. Non-insulin-dependent diabetic patients have a progressively reduced insulin secretion in relation to the increased disease duration. Diab Nutr Metab, 1991, 4, 107-111.
43. De Fronzo RA, Ferrannini AE. The pathogenesis of non-insulin-dependent diabetes: an update. Medicine (Baltimore), 1982, 61, 125-131.
44. Madsbad S, Faber OK, Binder C, McNair P, Christensen C, Transbol I. Prevalence of residual beta-cell function in insulin-dependent diabetics in relation to age at onset and duration of diabetes. Diabetes, 1982, 27 (Suppl. 1), 262-263.
45. Hsieh SD, Akahuma Y, Kawazu S, et al. Reduction of C-peptide secretion in non-insulin-dependent diabetic patients with long duration of insulin treatment. Endocrinol Japan, 1983, 30, 373-380.
46. Kosada K, Akanuma Y. Heterogeneity of plasma IRI responses in patients with IGT. Diabetologia, 1980, 18, 347-348.
47. Lev-Ran A, Hwang D, Barseghian G, Hill LR. Control of non-insulin-dependent diabetes is not correlated with endogenous insulin secretion. Diabete Metab, 1986, 12, 325-328.
48. Lohrmann D, Verlohren H-J. IRI-secretion in MOD with and without sulfonylurea (5-year control). Horm Metab Res, 1980, 12, 702-703.
49. Hockaday DR, Pierlussi R, Dhar H. Maturity-onset type diabetics show no consistent pattern of deterioration in insulin secretion over five years of diagnosis. Diabetologia, 1980, 19, 283-288.
50. Groop L, Tolppanen EM. Factors influencing beta-cell function and insulin sensitivity in patients with type 2 (non-insulin-dependent) diabetes. Acta Endocrinol, 1984, 106, 505-510.
51. Koskinen PS, Viikari JSA, Irjala KMA. Glucagon-stimulated and post-prandial plasma C-peptide values as measures of insulin secretory capacity. Diabetes Care, 1988, 11, 318-322.
52. Turkington RW, Estkowski A, Kink M. Secretion of insulin or connecting peptide, a predictor of insulin dependence of obese diabetics. Arch Int Med, 1982, 142, 1102-1105.
53. Hoekstra JBL, Van Rijn HJM, Thijssen JHH, Erkelens DW. C-peptide reactivity as a measure of insulin dependency in obese diabetic patients treated with insulin. Diabetes Care, 1982, 5, 585-591.
54. Rendell M. C-peptide levels as a criterion in treatment of maturity onset diabetes. J Clin Endocrinol Metab, 1983, 57, 1198-1206.
55. Grant PJ, Barlow E, Miles DW. Plasma C-peptide levels identify insulin-treated diabetic patients suitable for oral hypoglycaemic therapy. Diabetes Med, 1984, 1, 284-289.
56. Madsbad S, Krarup T, McNair P, et al. Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med Scand, 1981, 21, 153-156.
57. Laakso M, Sarlund H, Korhonen T, et al. Stopping insulin treatment in middle-aged diabetic patients with high postglucagon plasma C-peptide. Acta Med Scand, 1988, 223, 61-68.
58. Arner P, Pollare T, Lithell H. Different aetiologies of type 2 (non-insulin-dependent) diabetes mellitus in obese and non-obese subjects. Diabetalogia, 1991, 34, 483-487.